Recruitment
Elderly men and women were recruited from the Indianapolis area to participate in either a cross-sectional study (black and white participants) or cross-sectional and longitudinal study (white participants only) of dairy and bone density.
Design
- Cross-sectional study of dairy and BMD in black and white, men and women over the age of 60 years
- Longitudinal study of the effect daily calcium or vitamin D supplementation on preventing BMD loss in white men and women over the age of 60 years old.
Dietary Intake/Dietary Assessment Methodology
HHHQ-DIETSYS (National Cancer Institute) was used to collect dietary intake information. The questionnaire was modified to include yogurt and frozen yogurt to more completely capture dairy food intake.
Blinding Used
For longitudinal study, double-blinding for intervention was used.
Intervention
White subjects participated in a four-year, placebo-controlled study wherein participants received daily placebo, 750mg Ca per day, or 15mcg per day 25-hydroxyvitamin D3 per day.
Statistical Analysis
- Two-way ANOVA was used to examine differences in antropometric, micronutrient intake, dairy product intake associated with sex and race. Tukey's multiple comparison procedure was used to determine statistical differences between the four sex-by-race groups
- For the cross sectional data, partial correlations between BMD and nutrients from dairy and non-dairy sources, after removing the linear effects of race, weight and age, were examined. A partial regression plot was used to visually describe the adjusted relation between total hip BMD and dairy calcium intake in men and women
- For the longitudinal data, a repeated ANOVA was used to assess dietary information. Multiple regression models were used to evaluate the percentage change in total hip and femoral neck BMD in subjects that consumed less than or greater than 1.5 servings of dairy per day and in those who were older or younger than the median age of 72 years old
- SAS software was used for all statistical analysis.
|
Research Design and Implementation Criteria Checklist: Primary Research
|
|
Relevance Questions
|
| |
1.
|
Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) |
Yes
|
| |
2.
|
Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? |
Yes
|
| |
3.
|
Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to nutrition or dietetics practice? |
Yes
|
| |
4.
|
Is the intervention or procedure feasible? (NA for some epidemiological studies) |
Yes
|
| |
|
Validity Questions
|
| 1. |
Was the research question clearly stated? |
Yes
|
| |
1.1.
|
Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? |
Yes
|
| |
1.2.
|
Was (were) the outcome(s) [dependent variable(s)] clearly indicated? |
Yes
|
| |
1.3.
|
Were the target population and setting specified? |
Yes
|
| 2. |
Was the selection of study subjects/patients free from bias? |
Yes
|
| |
2.1.
|
Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? |
Yes
|
| |
2.2.
|
Were criteria applied equally to all study groups? |
Yes
|
| |
2.3.
|
Were health, demographics, and other characteristics of subjects described? |
Yes
|
| |
2.4.
|
Were the subjects/patients a representative sample of the relevant population? |
???
|
| 3. |
Were study groups comparable? |
Yes
|
| |
3.1.
|
Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) |
N/A
|
| |
3.2.
|
Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? |
No
|
| |
3.3.
|
Were concurrent controls used? (Concurrent preferred over historical controls.) |
Yes
|
| |
3.4.
|
If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? |
Yes
|
| |
3.5.
|
If case control or cross-sectional study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable. Criterion may not be applicable in some cross-sectional studies.) |
???
|
| |
3.6.
|
If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? |
N/A
|
| 4. |
Was method of handling withdrawals described? |
No
|
| |
4.1.
|
Were follow-up methods described and the same for all groups? |
Yes
|
| |
4.2.
|
Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) |
No
|
| |
4.3.
|
Were all enrolled subjects/patients (in the original sample) accounted for? |
No
|
| |
4.4.
|
Were reasons for withdrawals similar across groups? |
???
|
| |
4.5.
|
If diagnostic test, was decision to perform reference test not dependent on results of test under study? |
N/A
|
| 5. |
Was blinding used to prevent introduction of bias? |
Yes
|
| |
5.1.
|
In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? |
Yes
|
| |
5.2.
|
Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) |
???
|
| |
5.3.
|
In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? |
???
|
| |
5.4.
|
In case control study, was case definition explicit and case ascertainment not influenced by exposure status? |
N/A
|
| |
5.5.
|
In diagnostic study, were test results blinded to patient history and other test results? |
N/A
|
| 6. |
Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? |
???
|
| |
6.1.
|
In RCT or other intervention trial, were protocols described for all regimens studied? |
Yes
|
| |
6.2.
|
In observational study, were interventions, study settings, and clinicians/provider described? |
N/A
|
| |
6.3.
|
Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? |
Yes
|
| |
6.4.
|
Was the amount of exposure and, if relevant, subject/patient compliance measured? |
Yes
|
| |
6.5.
|
Were co-interventions (e.g., ancillary treatments, other therapies) described? |
N/A
|
| |
6.6.
|
Were extra or unplanned treatments described? |
N/A
|
| |
6.7.
|
Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? |
N/A
|
| |
6.8.
|
In diagnostic study, were details of test administration and replication sufficient? |
N/A
|
| 7. |
Were outcomes clearly defined and the measurements valid and reliable? |
Yes
|
| |
7.1.
|
Were primary and secondary endpoints described and relevant to the question? |
N/A
|
| |
7.2.
|
Were nutrition measures appropriate to question and outcomes of concern? |
Yes
|
| |
7.3.
|
Was the period of follow-up long enough for important outcome(s) to occur? |
Yes
|
| |
7.4.
|
Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? |
Yes
|
| |
7.5.
|
Was the measurement of effect at an appropriate level of precision? |
Yes
|
| |
7.6.
|
Were other factors accounted for (measured) that could affect outcomes? |
Yes
|
| |
7.7.
|
Were the measurements conducted consistently across groups? |
Yes
|
| 8. |
Was the statistical analysis appropriate for the study design and type of outcome indicators? |
No
|
| |
8.1.
|
Were statistical analyses adequately described and the results reported appropriately? |
No
|
| |
8.2.
|
Were correct statistical tests used and assumptions of test not violated? |
???
|
| |
8.3.
|
Were statistics reported with levels of significance and/or confidence intervals? |
Yes
|
| |
8.4.
|
Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? |
N/A
|
| |
8.5.
|
Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? |
N/A
|
| |
8.6.
|
Was clinical significance as well as statistical significance reported? |
???
|
| |
8.7.
|
If negative findings, was a power calculation reported to address type 2 error? |
No
|
| 9. |
Are conclusions supported by results with biases and limitations taken into consideration? |
No
|
| |
9.1.
|
Is there a discussion of findings? |
Yes
|
| |
9.2.
|
Are biases and study limitations identified and discussed? |
No
|
| 10. |
Is bias due to study’s funding or sponsorship unlikely? |
Yes
|
| |
10.1.
|
Were sources of funding and investigators’ affiliations described? |
Yes
|
| |
10.2.
|
Was the study free from apparent conflict of interest? |
Yes
|
| |
| |